Finanzen von MDxHealth SA (MDXH)MDXHMDxHealth SA

Evaluating the bottom line, MDxHealth SA maintains a gross margin of 61.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.74%, while the net margin is -34.83%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MDXH converts its operational activities into shareholder value.

In the context of the broader market, MDXH competes directly with industry leaders such as PAVM and ARAY. With a market capitalization of $17.56M, it holds a significant position in the sector. When comparing efficiency, MDXH's gross margin of 61.13% stands against PAVM's -269.70% and ARAY's 34.34%. Such benchmarking helps identify whether MDxHealth SA is trading at a premium or discount relative to its financial performance.

MDxHealth reported a Q2 2026 revenue of $27.2 million, a 16% increase year-over-year, but still posted a net loss of $11.5 million for the same quarter, reflecting ongoing financial struggles despite some revenue growth.